Compare Motorola Solutions Inc (MSI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Summit Therapeutics Inc — how do they compare? Motorola Solutions Inc trades at $463.3 (market cap $76.62B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Motorola Solutions Inc is far larger — about 5.6× Summit Therapeutics Inc's market cap, and Motorola Solutions Inc pays a 1.05% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MSI | SMMT | |
|---|---|---|
Market Cap | $76.62B | $13.79B |
Sector | Technology | Health |
52-Week High | $491.24 | $26.38 |
52-Week Low | $363.83 | $12.43 |
Enterprise Value | $85.53B | $13.11B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $462.98, down 1.08% on the day, amid a bullish technical setup with strong support at $459. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.41 surpassing the $3.85 estimate. Revenue growth is steady, reaching $11.68 billion in 2025, while net income margin improved to 17.44%. Recent news highlights a $2 billion share repurchase authorization and the completion of the $1.5 billion D-Fend Solutions acquisition, expanding its counter-drone portfolio.
The outlook remains positive given analyst consensus favoring Buy ratings (70.59%) and a price target of $536.50, implying ~16% upside. Key risks include elevated valuation multiples (P/E 36.48) and significant investing cash outflows ($-5.16 billion in 2025) from acquisitions. Execution on integration and debt management will be critical for sustaining shareholder value amid competitive pressures.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
